BioAtla IPO Presentation Deck

BA3011: Encouraging Results in NSCLC AXL High (TmPS 270) Patient at 1.8mg/kg Maximum Change From Baseline (%) 100 80 80 18 0 A 9 8 -100 AXL- TmPS=0 NSCLC (All Patients) TmPS=0 Not Evaluable Confirmed PR Stage IV adenocarcinoma (multiple chemo PKIs and pembrolizumab failure) AXL + TmPS=80 bicatla Note: All patients: Multiple cycles of antineoplastic agents received prior to starting treatment with BA3011 Stage IV adenocarcinoma patient case study • Patient experienced multiple failures of prior treatments . Prior treatment with PD- 1 inhibitor (pembrolizumab) failed -70% tumor reduction after BA3011 dosed at 1.8 mg/kg 2Q3W Out of 4 NSCLC patients, partial response achieved in the one patient with TmPS ≥ 70 13

View entire presentation